PapersFlow Research Brief
Lung Cancer Research Studies
Research Guide
What is Lung Cancer Research Studies?
Lung Cancer Research Studies is a body of scientific investigations focused on small cell lung cancer, examining genomic profiles, immunotherapy, chemotherapy, prognostic factors, biomarkers, targeted therapy, clinical trials, metastasis, and tumor markers.
The field encompasses 33,900 works on lung cancer research studies. These studies address small cell lung cancer through analyses of genomic profiles, immunotherapy responses, and chemotherapy outcomes. Key contributions include comparisons of immunotherapies like nivolumab against docetaxel in advanced non-small-cell lung cancer subtypes.
Topic Hierarchy
Research Sub-Topics
Small Cell Lung Cancer Genomic Profiles
Next-generation sequencing reveals recurrent mutations in TP53, RB1, and NOTCH family genes driving SCLC heterogeneity and evolution.
Immunotherapy in Small Cell Lung Cancer
Clinical trials of PD-1/PD-L1 inhibitors like nivolumab combined with chemotherapy, assessing immune checkpoint responses in extensive-stage disease.
Chemotherapy Regimens for Small Cell Lung Cancer
Optimization of platinum-etoposide doublets, maintenance strategies, and relapse management with topotecan or lurbinectedin.
Prognostic Biomarkers in Small Cell Lung Cancer
Validation of circulating tumor DNA, DLL3 expression, and lactate dehydrogenase levels predicting survival and treatment response.
Targeted Therapy in Small Cell Lung Cancer
Development of PARP inhibitors for SLFN11-high tumors and Aurora kinase antagonists exploiting SCLC replication stress.
Why It Matters
Lung cancer research studies guide clinical decisions in oncology by identifying superior treatments for advanced disease stages. For instance, H. Borghaei et al. (2015) in "Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer" showed longer overall survival with nivolumab compared to docetaxel in patients with advanced nonsquamous NSCLC post-platinum chemotherapy (9287 citations). Similarly, Julie R. Brahmer et al. (2015) in "Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer" demonstrated improved overall survival, response rate, and progression-free survival with nivolumab in squamous-cell NSCLC regardless of PD-L1 expression (8397 citations). Tony Mok et al. (2009) in "Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma" established gefitinib's superiority over carboplatin-paclitaxel for EGFR-mutated pulmonary adenocarcinoma in East Asian nonsmokers (8148 citations). Leena Gandhi et al. (2018) in "Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer" reported significantly longer survival with pembrolizumab added to pemetrexed-platinum chemotherapy in metastatic nonsquamous NSCLC without EGFR/ALK mutations (6336 citations). These findings shape targeted therapy and immunotherapy protocols in clinical practice.
Reading Guide
Where to Start
"Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer" by H. Borghaei et al. (2015), as it provides a clear comparison of immunotherapy versus chemotherapy with survival data from a large trial, serving as an accessible entry to treatment efficacy studies.
Key Papers Explained
H. Borghaei et al. (2015) in "Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer" established nivolumab's survival advantage in nonsquamous NSCLC, complemented by Julie R. Brahmer et al. (2015) in "Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer" extending benefits to squamous subtypes. Tony Mok et al. (2009) in "Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma" introduced EGFR-targeted therapy superiority, built upon by Rafael Rosell et al. (2012) in "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC)" confirming erlotinib in mutation-positive cases. Leena Gandhi et al. (2018) in "Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer" advanced combination immunotherapy-chemotherapy approaches.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Studies continue to explore immunotherapy and targeted therapy in small cell lung cancer subtypes, with emphasis on genomic profiles, biomarkers, and clinical trials for metastasis, as reflected in the cluster's focus on prognostic factors and tumor markers.
Papers at a Glance
Frequently Asked Questions
What survival benefits did nivolumab provide in advanced nonsquamous NSCLC?
In patients with advanced nonsquamous NSCLC progressed after platinum-based chemotherapy, overall survival was longer with nivolumab than docetaxel. This result came from the CheckMate 057 trial funded by Bristol-Myers Squibb. H. Borghaei et al. (2015) reported these outcomes in "Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer".
How did nivolumab compare to docetaxel in squamous-cell NSCLC?
Among patients with advanced squamous-cell NSCLC previously treated, nivolumab improved overall survival, response rate, and progression-free survival over docetaxel, independent of PD-L1 levels. Results stemmed from the CheckMate 017 trial. Julie R. Brahmer et al. (2015) detailed this in "Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer".
What role does EGFR mutation play in gefitinib treatment for pulmonary adenocarcinoma?
Gefitinib outperformed carboplatin-paclitaxel as initial treatment for pulmonary adenocarcinoma in East Asian nonsmokers or former light smokers. EGFR gene mutation in tumors strongly predicted better outcomes with gefitinib. Tony Mok et al. (2009) showed this in "Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma".
What were the results of adding pembrolizumab to chemotherapy in metastatic NSCLC?
In untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, pembrolizumab plus pemetrexed and platinum chemotherapy extended overall survival and progression-free survival beyond chemotherapy alone. Leena Gandhi et al. (2018) reported these findings in "Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer".
What did the EURTAC trial show for erlotinib in EGFR mutation-positive NSCLC?
Erlotinib as first-line treatment improved outcomes over standard chemotherapy in European patients with advanced EGFR mutation-positive NSCLC. The phase 3 trial was multicentre and open-label. Rafael Rosell et al. (2012) published results in "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial".
How effective is erlotinib in previously treated NSCLC?
Erlotinib prolonged survival in patients with non-small-cell lung cancer after first- or second-line chemotherapy. Frances A. Shepherd et al. (2005) demonstrated this in "Erlotinib in Previously Treated Non–Small-Cell Lung Cancer".
Open Research Questions
- ? How can biomarkers beyond EGFR and ALK mutations predict immunotherapy responses in small cell lung cancer?
- ? What genomic profiles distinguish metastatic progression in small cell lung cancer from nonsquamous subtypes?
- ? Which combinations of targeted therapies and chemotherapy optimize prognostic factors in extensive-stage small cell lung cancer?
- ? How do tumor markers influence clinical trial outcomes for immunotherapy in PD-L1-negative lung cancers?
- ? What mechanisms underlie chemotherapy resistance in small cell lung cancer metastasis?
Recent Trends
The field maintains 33,900 works on lung cancer research studies, with sustained focus on immunotherapy like nivolumab (H. Borghaei et al. 2015; Julie R. Brahmer et al. 2015) and targeted therapies such as gefitinib (Tony Mok et al. 2009) and erlotinib (Rafael Rosell et al. 2012; Frances A. Shepherd et al. 2005), alongside chemotherapy combinations (Leena Gandhi et al. 2018).
No recent preprints or news coverage from the last 12 months alters these established directions in small cell lung cancer genomic profiles, biomarkers, and clinical trials.
Research Lung Cancer Research Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Lung Cancer Research Studies with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers